Abstract. 5-Fluorouracil (5-FU) is a commonly used anti-tumor chemotherapeutic drug for cervical carcinoma. However, increased drug resistance may occur following several cycles of 5-FU-based chemotherapy. Novel strategies of gene therapy for enhancing the sensitivity of cancer cells to 5-FU chemotherapy have been intensively explored. Human telomerase reverse transcriptase (hTERT)C27 is a newly constructed hTERT C-terminal polypeptide that is capable of promoting chromosome end-to-end fusion during anaphase and inducing telomere dysfunction. In the present study, the effects of hTERTC27 overexpression on 5-FU-induced proliferation inhibition and apoptosis were observed. HeLa cells were cultured and transfected with the constructed pcDNA3.1 or pcDNA3.1-hTERTC27 vectors. Expression of hTERTC27 was detected using western blot analysis and was assessed using MTT assays and flow cytometry. The results demonstrated that overexpressed hTERTC27 increased the sensitivity of the HeLa cells to 5-FU and significantly inhibited HeLa cell proliferation with 5-FU treatment. In addition, hTERTC27 overexpression evidently promoted the 5-FU-induced apoptosis by increasing the expression of activated caspase-3 and -9 and by downregulating the expression of B-cell lymphoma 2. The results suggest that hTERTC27 overexpression is a potential clinical strategy for enhancing the antitumor effect of 5-FU chemotherapy in the treatment of cervical carcinoma.
Introduction
Cervical carcinoma is one of the most frequent types of cancer encountered in women (1) . Currently, 5-fluorouracil (5-FU), a commonly used antitumor chemotherapeutic drug, has been shown to be one of the standard chemoradiotherapy regimens in the treatment of many carcinomas including cervical cancer (2) (3) (4) . However, tumor recurrence and metastasis occur in a large number of cancer patients mainly due to limited drug sensitivity and an increased drug resistance (5) . Therefore, novel strategies of gene therapy for enhancing the sensitivity of cancer cells to drug-induced growth inhibition and apoptosis have been intensively explored (6) (7) (8) .
Telomerase is an attractive molecular target for cancer gene therapy due to its high prevalence in tumor cells (9) (10) (11) . Human telomerase is a ribonucleoprotein complex, which is composed of an RNA component hTR and telomerase reverse transcriptase (TERT), the catalytic protein subunit of telomerase (12) . The enzyme TERT is critical for maintaining the telomere length and prolonging the life span of cells, thereby contributing to uncontrolled cell proliferation (10) . Telomerase activity is markedly increased in the majority of tumors but not detected in the majority of normal cells. The reactivation of telomerase during carcinogenesis is a common hallmark in the majority of human tumors. In our previous study, hTERTC27, a 27 kDa C-terminal polypeptide of hTERT, was reported to clearly decrease cell proliferation and inhibit the tumorigenicity of human cervical carcinoma and glioblastoma by promoting chromosome end-to-end fusion during anaphase and by inducing telomere dysfunction (13) (14) (15) (16) To the best of our knowledge, the present is the first study to report the antitumor effects of 5-FU and overexpressed hTERTC27 on cervical carcinoma HeLa cells. Overexpressed hTERTC27 increased the sensitivity of the HeLa cells to 5-FU and significantly inhibited the HeLa cell proliferation with 5-FU treatment. In addition, hTERTC27 overexpression clearly promoted 5-FU-induced apoptosis by upregulating the expression of activated caspase-3 and -9, and downregulating the expression of B-cell lymphoma 2 (Bcl-2). These results indicate that overexpression of hTERTC27 may provide a novel approach for enhancing the sensitivity of 5-FU chemotherapy in the treatment of cervical carcinoma.
Materials and methods
Cell culture. Human cervical cancer HeLa cells were obtained from ATCC (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM; Hyclone Laboratories, Inc., South Logan, UT, USA), supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc.), 100 µg/ml penicillin (Ameresco, Middletown, CT, USA) and 100 µg/ml streptomycin (Ameresco). The cells were cultured at 37˚C in a humidified atmosphere with 5% CO 2 .
Transfection. The pcDNA3.1-hTERTC27 plasmid was maintained in our laboratory. cDNAs of a 27 kDa hTERT C-terminal polypeptide (hTERTC27, amino acid residues 882-1132) was constructed downstream. The HeLa cells were transfected with pcDNA3.1 vectors (known as control-HeLa cells) or pcDNA3.1-hTERTC27 vectors (termed C27-HeLa cells) using Lipofectamine 2000 transfection reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and following the manufacturer's instructions. The untransfected HeLa cells were designated as mock-HeLa cells. Twenty-four hours after transfection, the cells were treated with 5-FU and experiments were subsequently performed.
Western blot analysis. The expression of hTERTC27 was detected at 12, 24, 48 and 72 h after transfection. The expression of caspase-3, -9 and Bcl-2 was detected 48 h after 5-FU treatment. Western blot analysis was performed as described previously (17) . Antibodies against the hTERT COOH-terminal fragment (1:250; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), cleaved caspase-3 (1:1,000) and cleaved caspase-9 (1:1,000; both Cell Signaling Technology, Inc., Danvers, MA, USA) and Bcl-2 (1:500; Santa Cruz Biotechnology, Inc.) were used. The bound antibodies were located by further incubation with horseradish peroxidase-conjugated goat anti-rabblit IgG (1:5,000; Santa Cruz Biotechnology, Inc.). β-actin (1:500; Santa Cruz Biotechnology, Inc.) was used as a loading control. Blots were developed with an ECL plus kit (Pierce Biotechnology, Inc., Rockford, IL, USA), and exposed to Kodak film (Eastman Kodak Company, Rochester, NY, USA).
The National Institutes of Health Image program was used to quantify the intensity of the resulting bands.
MTT assay. In total, 2x10 3 HeLa cells (mock, control and C27) were seeded in a 96-well plate 24 h after transfection. After 12 h, the cells were treated with different concentrations (in µg/ml) of 5-FU of 0, 10, 20, 30, 40 or 50, respectively. The MTT assay was then performed at 12, 24, 48 and 72 h after 5-FU treatment. Briefly, 20 µl of 5 mg/ml MTT (Sigma, St. Louis, MO, USA) in PBS was added and the cells were incubated for 4 h at 37˚C with 5% CO 2 . The cells were washed twice with PBS and the pellet was then solubilized in 150 µl of 100% dimethylsulfoxide (Sigma) by agitating for 5 mins. The absorbance was measured on a microplate reader (Bio-Rad, Hercules, CA, USA) at a wavelength of 570 nm. The rate of cell viability was calculated according to the equation: A 570 (Cd)/A 570 (C 0 ) x 100.
A 570 (C 0 ) is the absorbance of the HeLa cells (mock, control and C27) without 5-FU treatment and A 570 (Cd) is the absorbance of the cells exposed to the different concentrations of 5-FU. All the experiments were performed in triplicate.
Colony formation assay. Twelve hours after transfection, control-HeLa and C27-HeLa cells were exposed to 20 µg/ml 5-FU, known as the 5-FU and C27+5-FU groups, respectively. The control-HeLa cells were exposed to PBS as a control, designated as the group control. After 12 h, the medium containing 5-FU was replaced. The cells were allowed to grow for 10 days, fixed with methanol for 10 min and stained with Giemsa for 15 min. The plates were washed and dried, and the colonies were counted. The experiments were performed in triplicate.
Flow cytometric analysis of apoptosis.
For a quantitative analysis of apoptosis, the cells were harvested 48 h after treatment with 20 µg/ml 5-FU, washed once in ice-cold PBS, incubated with annexin V-FITC/PI (Boehringer, Mannheim, Germany) in calcium containing HEPES (Sigma) buffer, and then immediately analyzed with a flow cytometry machine (Becton-Dickinson, Bedford, MA, USA).
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay.
The presence of apoptotic cells in the HeLa cells was detected by the TUNEL assay using the in situ cell death detection kit (POD; Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The apoptotic cells were analyzed under a fluorescence microscope (Olympus Corporation, Tokyo, Japan).
Statistical analysis. Data were presented as the mean ± SD. The results were compared by two-way analysis of variance. All the statistical calculations were performed with the SPSS11.0 software package (SPSS, Inc., Chicago, IL, USA). P<0.05 was used to indicate a statistically significant difference.
Results

hTERTC27 expression in HeLa cells following transfection.
Exogenous hTERTC27 protein was detected by western blot analysis at 12, 24, 48 and 72 h after transfection. As shown in Fig. 1A , the cells transfected with a recombinant plasmid containing hTERTC27 cDNA expressed hTERTC27 protein (27 kDa) slightly 12 h after transfection. After 24 h, the cells expressed the hTERTC27 protein in abundance. However, no exogenous hTERTC27 protein was detected in the non-transfected HeLa cells, and empty vector-transfected cells. Thus, the cells were treated with 5-FU 24 h following transfection in the subsequent experiments.
hTERTC27 enhances HeLa cell sensitivity to 5-FU treatment.
The effect of overexpressed hTERTC27 polypeptide on cell viability following treatment with different concentrations of 5-FU was determined at indicated time points by the MTT assay. As shown in Fig. 2 , the cell viability was markedly inhibited in the C27 group when compared with that in the mock group (P<0.01) and control (P<0.01). However, no signifi cant difference was observed between the mock group and the control (P>0.01). These results suggested that overexpressed hTERTC27 enhances the sensitivity of HeLa cells to 5-FU treatment and promotes 5-FU-induced growth inhibition. In order to perform subsequent experiments, a final concentration of 20 µg/ml 5-FU was selected to observe the effects of overexpressed hTERTC27 and 5-FU on HeLa cell proliferation and apoptosis.
hTERTC27 promotes inhibition of proliferation of HeLa cells with 5-FU treatment.
The control-HeLa and C27-HeLa cells were exposed to 20 µg/ml 5-FU (5-FU and C27+5-FU groups), and control-HeLa cells were exposed to PBS as a control (control group). As shown in Fig. 3A , the cell numbers were significantly decreased in the C27+5-FU (P<0.01) and 5-FU (P<0.01) groups when compared with that in the control group. Notably, the C27+5-FU group demonstrated a lower cell proliferation rate compared with that of the 5-FU group (P<0.01). A colony formation assay revealed that the colony formation rates in the 5-FU (2.63 ± 0.58%) and C27+5-FU (0.32 ± 0.09%) groups were significantly lower compared with that in the control (68.74 ± 8.62%) group (P<0.05) (Fig. 3B and C) . Moreover, the combined therapeutic group of C27+5-FU (0.3 ± 0.1%) demonstrated an additional decrease in the colony formation rate when compared with the 5-FU group alone. These results indicate that overexpressed hTERTC27 evidently inhibits the proliferation and colony formation in HeLa cells with 5-FU treatment. To determine whether hTERTC27 promotes apoptosis of HeLa cells, the TUNEL assay and annexin-V/PI double staining followed by a flow cytometry assay were performed. The apoptotic death (TUNEL positive) of the 5-FU group (39.28 ± 9.25%) was highly increased compared with that of the control group (1.66 ± 0.34%; (P<0.01). In addition, the combinatorial group of C27+5-FU (55.14 ± 11.67%) revealed a further increase in the TUNEL-positive rate when compared with the 5-FU group (P<0.05). To confirm this result, early apoptosis (annexin-V + /PI -) was assessed by flow cytometry (Fig. 4C and D) . Additionally, ~23% HeLa cells in group C27+5-FU were found to undergo early apoptosis, while only ~15% in the 5-FU and 2% in the control groups. These data indicate that hTERTC27 overexpression may promote the HeLa cell apoptosis induced by 5-FU.
hTERTC27 promotes the activation of caspases and the downregulation of Bcl-2 in HeLa cells with 5-FU treatment.
Apoptosis is known to be characterized by the activation of caspases. Thus, the effect of hTERTC27 and 5-FU was examined on the activation of caspase-3 and -9. As shown in Fig. 5 , the amount of caspase-3 activation was evidently enhanced in the C27+5-FU group when compared with that in the 5-FU group (P<0.01). Similar results were also observed in the activation of caspase-9. The changes in the signalling proteins were evaluated to be relevant to apoptosis. Bcl-2 is one of the most significant proteins of the antiapoptotic family. As shown in Fig. 5 , the Bcl-2 expression was markedly reduced in the C27+5-FU group when compared with that in the 5-FU group (P<0.01). These results consistently demonstrated that the overexpression of hTERTC27 clearly promoted 5-FU-induced apoptotic death in HeLa cells.
Discussion
In the present study, the overexpression of exogenous hTERTC27 was revealed to contribute to sensitizing HeLa cells to chemotherapeutic drugs such as 5-FU by promoting apoptosis. 5-FU, as an antimetabolic drug, is widely used in cancer chemotherapy due to its easy administration and high efficiency (3, 18) . However, long-term 5-FU chemotherapy is usually not administered to patients due to a decreasing sensitivity and side effects caused by the high dosage. Therefore, enhancing the sensitivity of cancer cells to 5-FU has become a crucial strategy for enhancing the antitumor effect of chemotherapeutic agents.
A number of therapeutic approaches are currently being explored to target telomere or telomerase for cancer therapy since telomerase is highly expressed in the majority of the tumors (11, 19) . The abnormal telomerase activity protects telomere from being shortened and therefore leads to uncontrollable cell proliferation ability and malignant transformation (10) . In our previous study, the ectopic expression of hTERTC27 was reported to lead to chromosome end-to-end fusion during anaphase and telomere dysfunction (13) . In the present study, hTERTC27 overexpression was demonstrated to increase the sensitivity of HeLa cells to 5-FU treatment by significantly inhibiting the cell viability. These changes resulted from the hTERTC27-induced increasing sensitivity of HeLa cells to the oxidative stress caused by 5-FU, which is consistent with the results of previous studies in which the overexpression of this polypeptide was observed to markedly enhance the sensitivity of HeLa cells to H 2 O 2 -induced injury (14) . These results indicated that a low concentration of 5-FU treatment in the presence of hTERTC27 may achieve the same therapeutic effect as a higher 5-FU concentration. This combinatorial strategy may decrease the therapeutic dose of 5-FU, and thus reduce the side effects of 5-FU chemotherapy.
The Bcl-2 family proteins are key regulators of cell apoptosis (20, 21) , and sequential activation of caspases has been revealed to be involved in cell apoptosis (22) . The activation of the caspase-3 pathway is a hallmark of apoptosis, and is activated in the apoptotic cell by extrinsic (death ligand) and intrinsic (mitochondrial) pathways (23) . Caspase-9, an initiator caspase, has been connected to the mitochondrial death pathway (24) . Once initiated, caspase-9 continues to cleave procaspase-3, leading to multiple cellular target cleavage including poly-ADP ribose polymerase (25) . In the present study it was found that 5-FU in combination with hTERTC27 significantly downregulated the expression of Bcl-2 and markedly promoted the activation of caspase-3 and -9, which confirmed that overexpression of the hTERTC27 polypeptide may enhance the antitumor effects of 5-FU by promoting cell apoptosis.
In conclusion, to the best of our knowledge, the present study reports for the first time the anticancer potential of the combination of 5-FU treatment and hTERTC27 overexpression. The overexpression of hTERTC27 was revealed to increase the sensitivity of cancer cells to 5-FU treatment. Furthermore, the combinatorial therapy was demonstrated to promote 5-FU-induced activation of caspase-3 and -9, and downregulate the expression levels of Bcl-2. Altogether, the present study has shown that the combination of 5-FU treatment and hTERTC27 overexpression may provide a potential 
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clinical strategy for enhancing the sensitivity of tumor cells to chemotherapy.
